Arlington, VA— The American Consumer Institute (ACI) submitted comments to the Department of Commerce and its Bureau of Industry and Security, with the goal of expressing concerns regarding the Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients. Imposing tariffs on imports of pharmaceutical products and active pharmaceutical ingredients (APIs) risks consumer welfare. Tariffs will increase medicine prices, exacerbating existing problems of drug affordability, and potentially cost lives, without increasing national security or pharmaceutical supply chain security.
Read the full comments below.